Biotech Values

[DewDiligence]

GILD—England will pay for ~500 HCV patients suffering from liver failure to be treated with Sovaldi in advance of a general reimbursement ruling by NICE:

http://finance.yahoo.com/news/england-agrees-funding-gilead-hepatitis-154349098.html

Health authorities in England have approved an 18.7 million pound ($31 million) investment to provide Gilead Sciences' controversial new hepatitis C pill Sovaldi for seriously ill patients. Healthcare provider NHS England said the decision would benefit about 500 patients suffering from acute liver failure, many of whom are awaiting a liver transplant.

The recommendation means that while Sovaldi has not yet been approved by the National Institute for Health and Clinical Excellence (NICE), the country's cost-effectiveness watchdog, it will be funded for those patients at significant risk of dying. NICE is due to publish its guidance on whether Sovaldi is worth using widely on the state-run National Health Service later this year.

Payment for the ~500 patients is at GILD’s UK commercial price of $57K for 12-week treatment.